Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 553 shares at $43.02 ($24K) on 2025-09-11, disclosed to the SEC on 2025-09-12.
Seasonal sale ($24k) by Chief Scientific Officer — this insider has traded AKRO in September in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $124K | — | Filing → |